| Heading: |
Blood Cancer: Medical Treatments |
| Question ID: |
1807455 |
| UIN: |
55888 |
| House: |
Commons |
| Date tabled: |
2025-05-30 |
| Asking Member ID: |
5359 |
| Asking Member display name: |
Neil Duncan-Jordan
|
| Asking Member handle: |
|
| Asking Member Twitter reference: |
Neil Duncan-Jordan
|
| Member interest: |
false |
| Question text: |
To ask the Secretary of State for Health and Social Care, what the reasons are for the higher level of NICE Health Technology Assessments of new blood cancer treatments that have been terminated compared to Health Technology Assessments for other forms of |
| Is named day: |
false |
| Date of holding answer: |
|
| Date answered: |
2025-06-06 |
| Date answer corrected: |
|
| Is holding answer: |
false |
| Is correcting answer: |
false |
| Answering Member ID: |
4444 |
| Answering Member display name: |
Karin Smyth
|
| Answering Member handle: |
karinsmyth
|
| Answering Member Twitter reference: |
@karinsmyth
|
| Correcting Member ID: |
|
| Correcting Member display name: |
|
| Correcting Member handle: |
|
| Correcting Member Twitter reference: |
|
| Answer text: |
In the last 10 years, where the National Institute for Health and Care Excellence (NICE) has been able to make a recommendation, 92% of blood cancer treatment recommendations were positive. This is significantly higher than the overall rate for cancer tre... |
| Original answer text: |
|
| Comparable answer text: |
|
| Answering body ID: |
17 |
| Answering body name: |
Department of Health and Social Care |
| Tweeted: |
true |